

# 3D Printed Drugs Market Industry Overview, Trends and Growth Opportunities Forecasted Till 2030

Rise in incidence of epilepsy and increasing awareness of 3D printing technology in developing countries are driving the 3D Printed Drugs market growth.

PORTLAND, OREGON, US, September 29, 2022 /EINPresswire.com/ -- 3D printed drugs are drugs created by 3D printing technology that are used to treat patients suffering from dysphagia. 3D printed drugs have a porous structure that can rapidly disintegrate in the mouth. Aprecia Pharmaceuticals Companys SPRITAM



levetiracetam is the first 3D printed drug, launched in the US in August 2015 approved by the Food and Drug Administration (FDA). Continuous technological developments in 3D printing techniques, rise in incidence of epilepsy and increasing awareness of 3D printing technology in developing countries are driving the <u>3D Printed Drugs market</u> growth. However, lack of government regulations related to these drugs and adverse effects of 3D printed drugs are expected to limit the market growth.

0000000 000000 000000 https://www.alliedmarketresearch.com/request-sample/4508

The analysis of the global 3D Printed Medicines market is based on forecast scenarios such as low growth scenario, medium growth scenario, and rapid growth scenario.

In a low growth scenario, the US will hold the highest market share in 2020 and the rest of North America market is expected to grow at the highest rate by 2030 registering a CAGR of 5.1%. Asia-Pacific is projected to grow at the highest growth rate during the analysis period due to rise in healthcare spending, increasing awareness related to 3D printing techniques, large patient population, and developments in healthcare infrastructure.

# 

#### 000 00000000:

- In North America, the US is projected to dominate the market in 2020, while the rest of North America is projected to grow at the highest CAGR during the forecast period.
- Germany was a major player in the European 3D printed medicine market in 2016.
- Asia-Pacific will register the highest growth rate in the future.
- Australia is expected to grow at the highest CAGR in the Asia-Pacific 3D printed medicine market.

### 0000000 000 0000000:

- · Aprecia Pharmaceuticals,
- · GlaxoSmithKline Plc.,
- · Hewlett Packard Caribe.
- BV,
- · LLC,
- 3D Printer Drug Machine,
- FabRx Ltd.

## 00000 00000000 0000000:

<u>Home Medical Equipment Market</u> <u>Orthopedic Implants Market</u>

#### 00000000:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

David Correa Allied Analytics LLP 800-792-5285 email us here Visit us on social media: Facebook

Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/593367581

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.